Find a clinical trial
Donate

This month's featured trials

Each month we will feature multiple trials, including one trial for idiopathic pulmonary fibrosis (IPF) patients and one trial for patients with other types of interstitial lung diseases (ILD) or related conditions. Please note, a full list of clinical trials can be found on the PFF Clinical Trial Finder.

Progressive Pulmonary Fibrosis 

MIST

Study ID: NCT06329401

Trial Phase: Phase 2b

Intervention: Inhaled drug

Sponsor: Avalyn Pharma Inc.

Contacts: MISTPPFStudy@avalynpharma.com or cconoscenti@avalynpharma.com; 206.707.0304

Find a trial
Drug details

Idiopathic Pulmonary Fibrosis

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

Study ID: NCT05195918

Trial Phase: Phase 1

Intervention: Oral Epigallocatechin-3-gallate

Sponsor: University of California, San Francisco

Contacts: ying.wei@ucsf.edu; 415.514.1209

Find a trial

Interstitial Lung Disease 

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

Study ID: NCT01280994

Trial Phase: Phase 2

Intervention: Hyperpolarized 129Xenon Gas

Sponsor: Bastiaan Driehuys and Duke University

Contacts: jennifer.korzekwinski@duke.edu; 919.681.7362

Find a trial

Study spotlight

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)


The U.S. Food and Drug Administration (FDA) has approved sotatercept-csrk (U.S. Brand Name: WINREVAIR™) for the treatment of adults with pulmonary arterial hypertension (PAH) to increase exercise capacity, improve the World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events. WINREVAIR was previously granted Breakthrough Therapy Designation by the FDA.


WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH. You can read the full announcement here and visit the WINREVAIR website for more information.

If you have any questions or comments about this newsletter, please contact partnerships@pulmonaryfibrosis.org. 

Quick Links



...About PF ... Breathe Bulletin ... Annual Report ... Contact us


Facebook  Twitter  Instagram  Linkedin  Youtube  
Disclaimer: The PFF does not promote or represent that any investigational new drugs mentioned are safe or effective. The information provided is for general information only and is not intended as medical or other professional advice. It should not be relied upon as a substitution for consultation with qualified professionals who are familiar with your individual needs. The PFF does not recommend any commercial product or services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

About the Pulmonary Fibrosis Foundation 

The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis. Until this goal is achieved, the PFF is committed to advancing improved care of patients with PF and providing unequaled support and education resources for patients, caregivers, family members, and health care providers. For more information, visit pulmonaryfibrosis.org or call 844.TalkPFF (844.825.5733) or +1 312.587.9272 from outside of the US. 


The Pulmonary Fibrosis Foundation rates among top charities in the U.S. The PFF has a four-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program® and has earned the Guidestar Platinum Seal of Transparency For more information, please visit our website.